| DB ID | MyCo_3121 |
| Title | Detection of (1,3)-β-d-Glucan in Cerebrospinal Fluid in Histoplasma Meningitis |
| Year | 2018 |
| PMID | 30021828 |
| Fungal Diseases involved | Histoplasmosis |
| Associated Medical Condition | Histoplasma Meningitis |
| Genus | Histoplasma |
| Species | spp. |
| Organism | Histoplasma spp. |
| Ethical Statement | None |
| Site of Infection | Central Nervous System |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Cerebrospinal fluid (CSF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | Forty-seven subjects with CNS histoplasmosis were enrolled in the study, including 9 (19.1%) confirmed, 33 (70.2%) probable, and 5 (10.6%) possible cases. A total of 153 subjects without CNS histoplasmosis were included as controls, including 13 (8.5%) with other causes of fungal meningitis, 31 (20.3%) with nonfungal meningitis, and 109 (71.2%) with noninfectious CNS disorders (e.g., encephalopathy or seizure disorder). |
| Cohort No. | 47 cases and 153 control |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.532 |
| Specificity | 0.869 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA approved Fungitell assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | FDA approved Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
